|
|
|
Insider
Information: |
Edelman Joseph |
Relationship: |
Former 10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
42 |
|
Direct
Shares |
630,171 |
|
Indirect Shares
|
332,164,708 |
|
|
Direct
Value |
$1,466,262 |
|
|
Indirect Value
|
$2,852,575,947 |
|
|
Total
Shares |
332,794,879 |
|
|
Total
Value |
$2,854,042,209 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
79
|
21
|
Stock
price went up :
|
50
|
11
|
Stock
price went down : |
29
|
10
|
|
|
|
Gain/Loss Ratio : |
1.7
|
1.1
|
Percentage
Gain/Loss : |
13.4%
|
197.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Penwest Pharmaceuticals Co |
PPCO |
10% Owner |
2008-06-23 |
0 |
2008-06-23 |
6,387,546 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
10% Owner |
|
0 |
2011-11-02 |
0 |
Premium* |
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
10% Owner |
2012-11-01 |
133,133 |
2012-11-29 |
2,595,293 |
Premium* |
|
Acelrx Pharmaceuticals Inc |
ACRX |
10% Owner |
|
0 |
2017-06-19 |
4,533,728 |
Premium* |
|
Amicus Therapeutics Inc |
FOLD |
10% Owner |
|
0 |
2018-10-03 |
20,724,424 |
Premium* |
|
VBI Vaccines Inc |
VBIV |
10% Owner |
|
0 |
2014-07-25 |
2,610,356 |
Premium* |
|
Aldeyra Therapeutics, Inc. |
ALDX |
10% Owner |
|
0 |
2024-04-05 |
9,275,851 |
Premium* |
|
Aravive Inc |
ARAV |
10% Owner |
|
0 |
2017-09-22 |
2,099,563 |
Premium* |
|
Kadmon Holdings, Llc |
KDMN |
10% Owner |
|
0 |
2019-11-18 |
14,636,334 |
Premium* |
|
Zogenix, Inc. |
ZGNX |
10% Owner |
2017-09-29 |
0 |
2018-08-10 |
4,070,357 |
Premium* |
|
Global Blood Therapeutics, Inc. |
GBT |
10% Owner |
2017-12-19 |
0 |
2017-12-19 |
4,889,066 |
Premium* |
|
Corium International, Inc. |
CORI |
10% Owner |
2018-01-16 |
0 |
2018-10-12 |
2,724,686 |
Premium* |
|
Albireo Pharma Inc |
ALBO |
10% Owner |
2018-01-25 |
0 |
2022-10-13 |
1,939,723 |
Premium* |
|
Solid Biosciences Inc |
SLDB |
Director, 10% Owner |
2018-01-30 |
0 |
2024-01-11 |
6,906,646 |
Premium* |
|
La Jolla Pharmaceutical Co |
LJPC |
10% Owner |
2018-02-13 |
0 |
2019-01-08 |
2,253,376 |
Premium* |
|
Motus Gi Holdings Inc |
MOTS |
10% Owner |
2018-02-16 |
0 |
2021-01-22 |
2,660,542 |
Premium* |
|
Quotient Ltd |
QTNTQ |
10% Owner |
2018-05-22 |
0 |
2022-10-31 |
7,945,211 |
Premium* |
|
Dova Pharmaceuticals, Inc. |
DOVA |
10% Owner |
2018-06-04 |
0 |
2019-11-12 |
0 |
Premium* |
|
Meiragtx Holdings Plc |
MGTX |
10% Owner |
2018-06-08 |
0 |
2023-05-05 |
11,281,103 |
Premium* |
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
10% Owner |
2018-07-20 |
0 |
2022-04-18 |
5,321,032 |
Premium* |
|
Agile Therapeutics Inc |
AGRX |
10% Owner |
2018-07-26 |
0 |
2021-10-13 |
21,654,485 |
Premium* |
|
Verrica Pharmaceuticals Inc. |
VRCA |
10% Owner |
2018-06-19 |
0 |
2023-12-29 |
7,099,182 |
Premium* |
|
Athenex, Inc. |
ATNX |
10% Owner |
2019-05-06 |
0 |
2020-09-14 |
13,532,467 |
Premium* |
|
ADMA Biologics Inc |
ADMA |
10% Owner |
2019-05-21 |
0 |
2021-09-30 |
13,262,375 |
Premium* |
|
Foamix Pharmaceuticals Ltd |
FOMX |
10% Owner |
|
0 |
2019-07-29 |
11,203,881 |
Premium* |
|
Lyra Therapeutics, Inc. |
LYRA |
Director, 10% Owner |
2020-05-05 |
0 |
2023-05-31 |
12,757,563 |
Premium* |
|
VYNE Therapeutics Inc |
VYNE |
10% Owner |
2020-06-09 |
0 |
2021-08-16 |
4,935,057 |
Premium* |
|
Leap Therapeutics, Inc. |
LPTX |
10% Owner |
2020-06-22 |
0 |
2020-06-22 |
8,476,496 |
Premium* |
|
Athira Pharma, Inc. |
ATHA |
Director, 10% Owner |
|
0 |
2023-12-29 |
5,402,964 |
Premium* |
|
Cerevel Therapeutics Holdings, I... |
CERE |
Director |
2020-10-20 |
0 |
2024-02-20 |
10,794,876 |
Premium* |
|
Scynexis Inc |
SCYX |
10% Owner |
2021-01-20 |
0 |
2021-01-22 |
1,800,000 |
Premium* |
|
Landos Biopharma, Inc. |
LABP |
Director, 10% Owner |
|
0 |
2021-02-09 |
17,960,839 |
Premium* |
|
Astria Therapeutics, Inc |
ATXS |
Director |
|
0 |
2024-02-01 |
6,485,420 |
Premium* |
|
Prometheus Biosciences, Inc. |
RXDX |
10% Owner |
2021-03-16 |
0 |
2021-03-16 |
3,314,032 |
Premium* |
|
Rain Therapeutics Inc. |
RAIN |
10% Owner |
2021-04-27 |
0 |
2021-10-12 |
2,487,019 |
Premium* |
|
Nautilus Biotechnology, Inc |
NAUT |
10% Owner |
2021-05-24 |
497,038 |
2021-12-08 |
9,111,151 |
Premium* |
|
Isoplexis Corp |
ISO |
10% Owner |
2021-10-12 |
0 |
2021-10-12 |
3,554,587 |
Premium* |
|
Lianbio |
LIAN |
Director, 10% Owner |
|
0 |
2024-02-15 |
57,575,533 |
Premium* |
|
Acrivon Therapeutics, Inc. |
ACRV |
10% Owner |
|
0 |
2024-04-11 |
5,360,858 |
Premium* |
|
Chembio Diagnostics Inc |
CEMI |
Former 10% Owner |
2023-04-04 |
0 |
2023-04-27 |
0 |
Premium* |
|
Soleno Therapeutics Inc |
SLNO |
10% Owner |
|
0 |
2023-06-06 |
2,207,753 |
Premium* |
|
Cargo Therapeutics, Inc. |
CRGX |
Former 10% Owner |
2023-11-14 |
0 |
2023-11-14 |
333,333 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
304 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 7 of 13
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ATHA |
Athira Pharma, Inc. |
Director |
|
2022-06-30 |
4 |
B |
$2.99 |
$3,293,072 |
I/I |
1,101,362 |
4,797,278 |
2.25 |
- |
|
ATHA |
Athira Pharma, Inc. |
Director |
|
2023-12-27 |
4 |
B |
$2.28 |
$73,266 |
I/I |
32,134 |
4,829,412 |
2.25 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-07-07 |
4 |
B |
$25.00 |
$5,000,000 |
I/I |
200,000 |
4,843,095 |
2.1 |
% |
|
CEMI |
Chembio Diagnostics Inc |
10% Owner |
|
2023-04-19 |
4 |
B |
$0.45 |
$61,376 |
I/I |
137,000 |
4,863,334 |
1.5 |
% |
|
ATXS |
Astria Therapeutics, Inc |
Director |
|
2024-02-01 |
4 |
B |
$12.09 |
$29,999,522 |
I/I |
2,481,350 |
4,873,721 |
2.1 |
% |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-08-23 |
4 |
B |
$25.78 |
$1,145,586 |
I/I |
44,437 |
4,887,532 |
2.1 |
% |
|
GBT |
Global Blood Therapeutics... |
10% Owner |
|
2017-12-19 |
4 |
B |
$38.00 |
$6,650,000 |
I/I |
175,000 |
4,889,066 |
1.5 |
- |
|
CEMI |
Chembio Diagnostics Inc |
10% Owner |
|
2023-04-20 |
4 |
B |
$0.45 |
$25,200 |
I/I |
56,000 |
4,919,334 |
1.5 |
% |
|
VYNE |
VYNE Therapeutics Inc |
10% Owner |
|
2021-08-16 |
4 |
S |
$1.74 |
$435,000 |
I/I |
(250,000) |
4,935,057 |
0 |
% |
|
KDMN |
Kadmon Holdings, Llc |
10% Owner |
|
2017-03-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,955,474 |
|
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-08-24 |
4 |
B |
$27.73 |
$1,934,473 |
I/I |
69,761 |
4,957,293 |
2.1 |
% |
|
CEMI |
Chembio Diagnostics Inc |
10% Owner |
|
2023-04-21 |
4 |
B |
$0.45 |
$31,450 |
I/I |
70,200 |
4,989,534 |
1.5 |
% |
|
ACRX |
Acelrx Pharmaceuticals In... |
10% Owner |
|
2012-12-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,008,400 |
|
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-08-25 |
4 |
B |
$28.57 |
$1,753,827 |
I/I |
61,387 |
5,018,680 |
2.1 |
% |
|
CEMI |
Chembio Diagnostics Inc |
10% Owner |
|
2023-04-24 |
4 |
B |
$0.45 |
$17,778 |
I/I |
39,506 |
5,029,040 |
1.5 |
% |
|
VRCA |
Verrica Pharmaceuticals I... |
10% Owner |
|
2022-07-05 |
4 |
B |
$2.10 |
$2,999,999 |
I/I |
1,428,571 |
5,038,983 |
1.5 |
% |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-08-26 |
4 |
B |
$30.23 |
$2,057,061 |
I/I |
68,047 |
5,086,727 |
2.1 |
% |
|
CEMI |
Chembio Diagnostics Inc |
10% Owner |
|
2023-04-25 |
4 |
B |
$0.45 |
$60,184 |
I/I |
133,742 |
5,162,782 |
1.5 |
% |
|
CRNX |
Crinetics Pharmaceuticals... |
10% Owner |
|
2021-10-25 |
4 |
B |
$19.80 |
$23,760,000 |
I/I |
1,200,000 |
5,163,517 |
1.5 |
% |
|
VYNE |
VYNE Therapeutics Inc |
10% Owner |
|
2021-08-13 |
4 |
S |
$1.84 |
$460,000 |
I/I |
(250,000) |
5,185,057 |
0 |
% |
|
ATHA |
Athira Pharma, Inc. |
Director |
|
2023-12-28 |
4 |
B |
$2.44 |
$999,419 |
I/I |
409,598 |
5,239,010 |
2.25 |
- |
|
CRNX |
Crinetics Pharmaceuticals... |
10% Owner |
|
2022-04-18 |
4 |
B |
$22.22 |
$3,499,983 |
I/I |
157,515 |
5,321,032 |
1.5 |
% |
|
ACRV |
Acrivon Therapeutics, Inc... |
10% Owner |
|
2024-04-11 |
4 |
B |
$8.50 |
$20,000,500 |
I/I |
2,353,000 |
5,360,858 |
1.5 |
% |
|
ATHA |
Athira Pharma, Inc. |
Director |
|
2023-12-29 |
4 |
B |
$2.38 |
$390,211 |
I/I |
163,954 |
5,402,964 |
2.25 |
- |
|
VYNE |
VYNE Therapeutics Inc |
10% Owner |
|
2021-08-12 |
4 |
S |
$2.23 |
$755,740 |
I/I |
(338,897) |
5,435,057 |
0 |
% |
|
304 Records found
|
|
Page 7 of 13 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|